{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T08:28:24Z","timestamp":1721377704298},"reference-count":41,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2013]]},"DOI":"10.3960\/jslrt.53.141","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T23:14:14Z","timestamp":1377904454000},"page":"141-150","source":"Crossref","is-referenced-by-count":3,"title":["Double-Hit Lymphoma Demonstrating t(6;14;18)(p25;q32;q21), Suggesting Two Independent Dual-Hit Translocations, MYC\/BCL-2 and IRF4\/BCL-2"],"prefix":"10.3960","volume":"53","author":[{"given":"Rie","family":"Tabata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Yasumizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, <I>et al<\/I>.: Double-hit B-cell lymphomas. Blood 117:2319-2331, 2011","DOI":"10.1182\/blood-2010-09-297879"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Salaverria I, Siebert R: The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 29:1835-1843, 2011","DOI":"10.1200\/JCO.2010.32.8385"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpointof neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099, 1984","DOI":"10.1126\/science.6093263"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, <I>et al<\/I>.: The c-Myc target gene network. Semin Cancer Biol 16:253-264, 2006","DOI":"10.1016\/j.semcancer.2006.07.014"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Wu D, Wood BL, Dorer R, Fromm JR: &ldquo;Double-Hit&rdquo; mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. Am J Clin Pathol 134:258-265, 2010","DOI":"10.1309\/AJCP7YLDTJPLCE5F"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, <I>et al<\/I>.: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34:327-340, 2010","DOI":"10.1097\/PAS.0b013e3181cd3aeb"},{"key":"7","unstructured":"7 Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, <I>et al<\/I>.: B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25:145-156, 2012"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kanungo A, Medeiros LJ, Abruzzo LV, Lin P: Lymphoid neoplasms associated with concurrent t(14;18) and 8q24\/c-MYC translocation generally have a poor prognosis. Mod Pathol 19:25-33, 2006","DOI":"10.1038\/modpathol.3800500"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Carbone A, Gloghini A, Aiello A, Testi A, Cabras A: B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol 41:621-631, 2010","DOI":"10.1016\/j.humpath.2009.10.027"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, <I>et al<\/I>.: Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 94:935-943, 2009","DOI":"10.3324\/haematol.2008.005355"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, <I>et al<\/I>.: Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 96:1327-1334, 2011","DOI":"10.3324\/haematol.2011.042531"},{"key":"12","unstructured":"12 Shiozawa E, Yamochi-Onizuka T, Yamochi T, Yamamoto Y, Naitoh H, <I>et al<\/I>.: Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma : immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract 199:293-302, 2003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 de Jong D: Novel lymphoid neoplasms -the borderland between diffuse large B-cell lymphoma and Burkitt's lymphoma. Haematologica 94:894-896, 2009","DOI":"10.3324\/haematol.2009.008128"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, <I>et al<\/I>.: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement. Haematologica 92:1335-1342, 2007","DOI":"10.3324\/haematol.11305"},{"key":"15","unstructured":"15 Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, <I>et al<\/I>.: Lymphomas with concurrent BCL2 and MYC translocations : the critical factors associated with survival. Blood 114:2273-2279, 2009"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, <I>et al<\/I>.: IRF4 addiction in multiple myeloma. Nature 454:226-231, 2008","DOI":"10.1038\/nature07064"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Maleki A, Seegmiller AC, Uddin N, Karandikar NJ, Chen W: Bright CD38 expression is an indicator of MYC rearrangement. Leuk Lymphoma 50:1054-1057, 2009","DOI":"10.1080\/10428190902930470"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Lossos IS, Gascoyne RD: Transformation of follicular lymphoma. Best Pract Res Clin Haematol 24:147-163, 2011","DOI":"10.1016\/j.beha.2011.02.006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Grumont RJ, Gerondakis S: Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes : modulation of interferon-regulated gene expression by rel\/nuclear factor &kappa;B. J Exp Med 191:1281-1292, 2000","DOI":"10.1084\/jem.191.8.1281"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Mittr&uuml;cker HW, Matsuyama T, Grossman A, K&uuml;ndig TM, Potter J, <I>et al<\/I>.: Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function. Science 275:540-543, 1997","DOI":"10.1126\/science.275.5299.540"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Gupta S, Jiang M, Anthony A, Pernis AB: Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med 190:1837-1848, 1999","DOI":"10.1084\/jem.190.12.1837"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, <I>et al<\/I>.: A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12:280-292, 2007","DOI":"10.1016\/j.ccr.2007.08.011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, <I>et al<\/I>.: Signatures of the immune response. Immunity 15:375-385, 2001","DOI":"10.1016\/S1074-7613(01)00194-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 . Shaffer AL, Emre NC, Romesser PB, Staudt LM: IRF4 : Immunity. Malignancy ! Therapy ? Clin Cancer Res 15:2954-2961, 2009","DOI":"10.1158\/1078-0432.CCR-08-1845"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, <I>et al<\/I>.: Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25:225-236, 2006","DOI":"10.1016\/j.immuni.2006.07.009"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, <I>et al<\/I>.: A novel interferon regulatory factor family transcription factor, ICSAT\/Pip\/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol 16:1283-1294, 1996","DOI":"10.1128\/MCB.16.4.1283"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Xu D, Zhao L, Del Valle L, Miklossy J, Zhang L: Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol 82:6251-6258, 2008","DOI":"10.1128\/JVI.00163-08"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Shapiro-Shelef M, Calame K: Regulation of plasma-cell development. Nat Rev Immunol 5:230-242, 2005","DOI":"10.1038\/nri1572"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Tarlinton D, Radbruch A, Hiepe F, D&ouml;rner T: Plasma cell differentiation and survival. Curr Opin Immunol 20:162-169, 2008","DOI":"10.1016\/j.coi.2008.03.016"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Schmidlin H, Diehl SA, Blom B: New insights into the regulation of human B-cell differentiation. Trends Immunol 30:277-285, 2009","DOI":"10.1016\/j.it.2009.03.008"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Shaffer AL, Wright G, Yang L, Powell J, Ngo V, <I>et al<\/I>.: A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210:67-85, 2006","DOI":"10.1111\/j.0105-2896.2006.00373.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Brass AL, Kehrli E, Eisenbeis CF, Storb U, Singh H: Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU. 1. Genes Dev 10:2335-2347, 1996","DOI":"10.1101\/gad.10.18.2335"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, <I>et al<\/I>.: MUM1\/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 14:449-456, 2000","DOI":"10.1038\/sj.leu.2401696"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, <I>et al<\/I>.: A monoclonal antibody (MUM1p) detects expression of the MUM1\/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084-2092, 2000","DOI":"10.1182\/blood.V95.6.2084"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, <I>et al<\/I>.: Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118:139-147, 2011","DOI":"10.1182\/blood-2011-01-330795"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Yanai H, Negishi H, Taniguchi T: The IRF family of transcription factors : Inception, impact and implications in oncogenesis. Oncoimmunology 1:1376-1386, 2012","DOI":"10.4161\/onci.22475"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Grumont RJ, Strasser A, Gerondakis S: B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel\/NF-&kappa;B regulated c-myc transcription. Mol Cell 10:1283-1294, 2002","DOI":"10.1016\/S1097-2765(02)00779-7"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, <I>et al<\/I>.: Small molecule inhibitors of I&kappa;B-kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40, 2005","DOI":"10.1158\/1078-0432.28.11.1"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, <I>et al<\/I>.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002","DOI":"10.1200\/JCO.2002.01.133"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, <I>et al<\/I>.: Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 115:475-480, 2010","DOI":"10.1182\/blood-2009-08-233155"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, <I>et al<\/I>.: IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One 6:e22628, 2011","DOI":"10.1371\/journal.pone.0022628"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T07:12:57Z","timestamp":1688454777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/53\/2\/53_141\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.53.141","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}